| Literature DB >> 30513764 |
Amrik Singh Gill1, Hana Morrissey2, Ayesha Rahman3.
Abstract
Background and objectives: The use of antibiotic prophylaxis in extraction and implant dentistry is still controversial, with varying opinions regarding their necessity. The overuse of antibiotics has led to widespread antimicrobial resistance and the emergence of multi drug resistant strains of bacteria. The main aim of this work was to determine whether there is a genuine need for antibiotic prophylaxis in two common dental procedures; dental implants and tooth extractions.Entities:
Keywords: antibiotic prophylaxis; dental extraction; dental implants; microbial drug resistance
Mesh:
Substances:
Year: 2018 PMID: 30513764 PMCID: PMC6306745 DOI: 10.3390/medicina54060095
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Summary of commonly prescribed antimicrobial drugs in dentistry in the UK. Adapted from Ramu & Padmanabhan (2012) and the British National Formulary (BNF, 2013) [21,22].
| Antibiotic | Class | Drug Mechanism | Spectrum of Activity | Common Indications in Dentistry | Dose Range | Comments |
|---|---|---|---|---|---|---|
| Amoxicillin | Penicillin | Inhibits biosynthesis of cell wall | Broad spectrum. Active against certain gram + and gram − organisms | Dentoavleolar abscess | 250 mg three times daily (dose can be doubled in severe infections) | Just as effective as phenoxymethyl penicillin but better absorbed. Ineffective to beta lactamase producing organisms. |
| Ampicillin | Penicillin | Inhibits biosynthesis of cell wall | Broad spectrum. Active against certain gram + and gram − organisms | Dentoavleolar abscess | 500–1000 mg four times daily | See amoxicillin |
| Penicillin V Phenoxymethylpenicillin | Penicillin | Inhibits biosynthesis of cell wall | More active against gram + than gram - | Dentoavleolar abscess. Should not be used in serious infections. | 500 mg four times daily (dose can be doubled in severe infections) | Gastric acid-stable therefore suitable for oral administration unlike penicillin G |
| Co-Amoxiclav | Penicillin | Inhibits biosynthesis of cell wall | Broad spectrum. Active against beta-lactamase producing bacteria resistant to amoxicillin | Severe dental infection with spreading cellulitis or dental infection non-responsive to 1st line antibacterial. | 250 mg/125 mg (ampicillin/clauvic acid) combination tablet three times daily (higher dose of 500 mg/125 mg in severe infections) | A mixture of clauvulanic acid acting as beta-lacamase inhibitor (as potassium clavulanate) and amoxicillin (as trihydrate/sodium salt) |
| Cefalexin | Cephalosporin | Binds to penicillin binding proteins and inhibits cell wall synthesis. | More active against aerobes | Dental infections resistant to penicillin VK | 250–1500 mg four times daily | Offer little advantage over penicillin’s in dental infections but useful in those with hypersensitivity to penicillin’s |
| Cefradine | Cephalosporin | Binds to penicillin binding proteins and inhibits cell wall synthesis. | More active against aerobes | Dental infections resistant to penicillin VK | 250–1000 mg four times daily | See Cephalexin |
| Metronidazole | Metronidazole | Inhibiting nucleic acid synthesis | High activity against anaerobic bacteria and protozoa | Acute necrotising gingivitis, pericoronitis | 200–250 mg three times daily | High concentration builds up achievable in tissue. |
| Clarithromycin | Macrolide | Inhibits bacterial peptide translation | Similar but not identical to penicillin | 2nd line drug treatment for dental abscess | 250–500 mg twice daily | Many organisms rapidly develop resistance to macrolides; use should be limited to short courses |
| Doxycycline | Tetracycline | Inhibits bacterial protein synthesis | Effective against oral anaerobes. | Sinusitis | 200 mg initially, 100 mg daily | Due to antibiotic resistance, especially by oral streptococci, tetracycline usefulness is reduced in acute oral infections. |
* Local formulary dose recommendation may differ to BNF doses.
Rationale for each level of bias.
| Level of Bias | Description |
|---|---|
| High risk | Possible bias seriously affecting the reliability of the results and high risk of bias if one or more of the criteria were not met |
| Low risk | Possible bias not seriously affecting the reliability of the results and low risk of bias if all criterion met |
Figure 1Flowchart showing the article selection process.
Risk of bias for studies based on 4 main criteria recommend by Cochrane Handbook for systematic reviews of interventions Version 5.1.0.
| Study | Patient Blinding | Assessor Blinding | Allocation Concealment | Withdrawals | Risk of Bias |
|---|---|---|---|---|---|
| Anitua et al. (2009) | Yes | Yes | Concealed | None | Low |
| Caiazzo et al. (2011) | Yes | Yes | Unclear | None | High |
| Esposito et al. (2010) | Yes | Yes | Concealed | Yes (enough reasons have been provided) | Low |
| Sekhar et al. (2001) | Yes | Yes | Concealed | Yes | High |
| Dios et al. (2006) | Yes | Yes | Concealed | None | Low |
| Kaczmarzyk et al. (2007) | Yes | Yes | Concealed | Yes | High |
| Lacasa et al. (2007) | Yes | Yes | Unclear risk | None | Low |
A summary of study population characteristics.
| Study (Author) | Extraction/Implant | Intervention | Number of Participants | Gender (m/f) | Mean Age (Years) | Number of Extractions/Implants |
|---|---|---|---|---|---|---|
| Caiazzo et al. | Implant | Amoxicillin 2 g 1 h pre-op | 25 | 13/12 | 52 | 35 |
| Amoxicillin 2 g 1 h pre-op + amoxicillin 2 g daily for 7 days post-op | 25 | 12/13 | 45 | 36 | ||
| Amoxicillin 2 g daily post-op for 7 days | 25 | 7/18 | 42 | 48 | ||
| No antibiotic | 25 | 10/15 | 43 | 29 | ||
| Anitua et al. | Implant | Amoxicillin 2 g 1 h pre-op | 52 | 15/37 | 49 | 52 |
| Placebo (identical tablests) 2 g 1 h pre-op | 53 | 20/33 | 47 | 53 | ||
| Esposito et al. | Implant | Amoxicillin 2 g 1 h pre-op | 252 | 114/138 | 49.1 | 489 |
| Placebo (no antibiotic) | 254 | 122/132 | 47.6 | 483 | ||
| Sekhar et al. | Extraction | Metronidazole 1 g orally 1 h preoperatively | 44 | 25/19 | 28 | 99 |
| Metronidazole 400 mg orally 4 times daily for 5 days | 47 | 30/17 | 29 | 101 | ||
| placebo | 34 | 15/19 | 26 | 103 | ||
| Dios et al. | Extraction | Amoxicillin 2 g preoperatively | 56 | 34/22 | 23.8 | 56 |
| moxifloxacin 400 mg preoperatively | 58 | 29/29 | 22.4 | 58 | ||
| clindamycin 600 mg preoperatively | 54 | 34/20 | 24 | 54 | ||
| Placebo | 53 | 29/24 | 26.1 | 53 | ||
| Kaczmarzyk et al. | Extraction | Clindamycin 600 mg preoperatively then 300 mg placebo for 5 days | 31 | 8/23 | 23.4 | 31 |
| Clindamycin 600 mg preoperatively then 300 mg placebo for 5 days post-op | 28 | 9/19 | 23.5 | 28 | ||
| placebo | 27 | 6/21 | 24.6 | 27 | ||
| Lacasa et al. | Extraction | Pre-op amoxicillin/clavulanate 2000/125 mg | 75 | 33/42 | 29.7 | 75 |
| post-op amoxicillin/clavulanate 2000/125 mg | 75 | 37/38 | 29.5 | 75 | ||
| placebo | 75 | 26/49 | 28.2 | 75 |
A summary of key characteristics for randomised clinical extraction studies evaluating the effectiveness of antibiotics in preventing post-operative complications.
| Study | Complication/Procedure | Intervention | Patient Sample Size | Study Design | Outcomes Assessed | Location | Results | Comments |
|---|---|---|---|---|---|---|---|---|
| Sekhar et al. (2001) | Lower wisdom tooth extraction | Metronidazole 1 g orally 1h preoperatively vs. metronidazole 400 mg orally 4 times daily for 5 days vs placebo | 3-arm, randomised, double blind | Purulent discharge from wound, dry socket, swelling, pain score | India | Overall, no significant differences in groups from any of the variables. | Outcome assessment procedures were not clearly specified. No power analysis performed. At enrolment patients’ key characteristics not fully assessed. | |
| Kaczmarzyk et al. (2007) | Extraction of third molar tooth. | Clindamycin 600 mg preoperatively then 300 mg placebo vs. Clindamycin 600 mg preoperatively then 300 mg placebo post-op vs. placebo (5 day treatment) | 3-arm prospective, randomised, double blind | Using 4-grade scale: Trismus, facial swelling, pain, body temperature & alveolar osteitis. All evaluated on day 1, 2 and 7 (post-op) | Poland | No statistically significant differences in post-op complication rates for third molar extraction from any group. | Incomplete outcome data (attrition bias)—14% patients lost at follow up. Inclusion criteria basic. Exclusion criteria well described. Power analysis performed. Demographic, objective and subjective data clearly defined. | |
| Dios et al. (2006) | Tooth extraction for any indication | Amoxicillin 2 g preoperatively vs. moxifloxacin 400 mg vs. clindamycin 600mg (preoperatively vs. placebo | 3-arm, randomised, double blind | Postoperative bacteraemia levels determined by microbiological analysis of blood cultures. | Spain | Postoperative measurements of bacteraemia showed decrease in amoxicillin and moxifloxacin | Clear exclusion criteria described, however unclear description of inclusion criteria. Power analysis performed. | |
| Lacasa et al. (2006) | Third mandibular surgery required | Pre-op amoxicillin/clavulanate 2000/125 mg vs. post-op amoxicillin/clavulanate 2000/125 mg vs. placebo | 3-arm randomised, double blind, parallel, phase III comparative study | Infection (purulent discharge in surgical site, pain, local abscess, increased heat, pyrexia, trismus, dental osteitis. All evaluated on days 1,3,7 post-op. | Spain | Higher rate of infection was seen in placebo group (16%) vs. single dose prophylaxis (5.3%) vs. 5 day pre-emptive therapy (2.7%) | Patients lost at each follow up not mentioned. Incomplete outcome data (attrition bias). Randomisation method not clearly defined. Two authors are employed by the funding company. |
A summary of key characteristics for randomised clinical implant studies evaluating the effectiveness of antibiotics in preventing implant failure.
| Study | Complication/Procedure | Intervention | Sample Size | Study Design | Outcomes Assessed | Location | Results | Comments |
|---|---|---|---|---|---|---|---|---|
| Caiazzo et al. (2010) | Dental implant surgery | Amoxicillin 2 g pre-op vs. Amoxicillin 2 g daily pre & post-op (7days) vs. amoxicillin 2 g post-op (7days) vs. placebo | 4-arm, prospective, multicentre parallel, randomised, study | Implant failure, postoperative complications assessed post-op at weeks 1,2,4 and 8, adverse events | Italy | Overall success rate 98.65%. No significant differences between expt. groups ( | Allocation concealment information not provided. | |
| Esposito et al. (2010) | Dental implant surgery | Amoxicillin 2g pre-op vs. placebo | Randomised, multicentre, double blind, placebo controlled & parallel (4 month duration) | Implant & prosthesis failure. Post-op complications (assessed weeks 1 & 2 post-op), and adverse events. | Italy | No statistically significant differences observed between groups but trend favoured antibiotic administration. More implant losses in placebo group | Limitations of the study well described. Allocation concealment information well provided. Information provided for blinding of operators. All outcome measures reported. | |
| Anitua et al. (2009) | Dental implant surgery | Amoxicillin 2g preoperatively vs. moxifloxacin 400 mg vs clindamycin 600 mg preoperatively vs placebo | Randomised, multicentre, double blind, parallel, placebo controlled | Postoperative infections, microbiological analysis, adverse events and implant failures. | Spain | Six post op infections occurred and 2 implant failures in each group. No statistically significant differences observed between groups. | No patient drop outs. |
Figure 2A forest plot of comparison showing antibiotics vs. placebo/no antibiotics for implant failure.
Figure 3A forest plot of comparison showing antibiotics vs. placebo/no antibiotics for adverse events.
Number need to treat calculation.
| Numbers Need to Treat (NNT) |
|---|
| Control group event rate (CER): proportion of outcomes that occur in control group. |
Figure 4A forest plot of comparison showing antibiotics vs. placebo/no antibiotics for postoperative complications.